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E-mail address: neurosaitoh@mbk.nifty.com (Y. SaThere is little evidence for multisession repetitive transcranial magnetic stimulation (rTMS) on pain relief
in patients with neuropathic pain (NP), although single-session rTMS was suggested to provide transient
pain relief in NP patients. We aimed to assess the efﬁcacy and safety of 10 daily rTMS in NP patients. We
conducted a randomized, double-blind, sham-controlled, crossover study at 7 centers. Seventy NP
patients were randomly assigned to 2 groups. A series of 10 daily 5-Hz rTMS (500 pulses/session) of pri-
mary motor cortex (M1) or sham stimulation was applied to each patient with a follow-up of 17 days. The
primary outcome was short-term pain relief assessed using a visual analogue scale (VAS). The secondary
outcomes were short-term change in the short form of the McGill pain questionnaire (SF-MPQ), cumula-
tive changes in the following scores (VAS, SF-MPQ, the Patient Global Impression of Change scale [PGIC],
and the Beck Depression Inventory [BDI]), and the incidence of adverse events. Analysis was by intention
to treat. This trial is registered with the University hospital Medical Information Network Clinical Trials
Registry. Sixty-four NP patients were included in the intention-to-treat analysis. The real rTMS, compared
with the sham, showed signiﬁcant short-term improvements in VAS and SF-MPQ scores without a carry-
over effect. PGIC scores were signiﬁcantly better in real rTMS compared with sham during the period
with daily rTMS. There were no signiﬁcant cumulative improvements in VAS, SF-MPQ, and BDI. No seri-
ous adverse events were observed. Our ﬁndings demonstrate that daily high-frequency rTMS of M1 is tol-
erable and transiently provides modest pain relief in NP patients.
 2013 International Association for the Study of Pain. Published by Elsevier B.V.Open access under CC BY-NC-ND license. 1. Introduction
Neuropathic pain (NP) is one type of refractory chronic pain
condition [6]. The annual incidence of NP has been reported to
be 0.82% [8] and the prevalence of neuropathic characteristics with
chronic pain has been reported as 6.9% in the general population
[5]. The medical treatments for NP often fail to relieve the pain,tudy of Pain. Published by Elsevie
of Neuromodulation and
ration, Osaka University, 2-1
1 6 6879 4138.
itoh).and symptoms are persistent. These painful conditions often
disturb the activities of daily living and reduce the quality of life
for patients [6].
For these refractory disease conditions, electrical motor cortex
stimulation (EMCS) targeting the primary motor cortex (M1) has
provided pain relief in about half of patients [38]. However, EMCS
requires an invasive implantation of intracranial electrodes and a
pulse generator. According to recent reports, including ours, nonin-
vasive high-frequency (HF) (P5 Hz) repetitive transcranial mag-
netic stimulation (rTMS) of M1 can have pain-relieving effects in
NP patients [3,14,15,17,21–25,27,31,36]. Most previous reportsr B.V. Open access under CC BY-NC-ND license. 
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of rTMS. The reported effect of a single-session of rTMS is transient,
lasting from several hours up to a week [14,15,25,36]. Based on
these results, repeated administration of rTMS, like daily stimula-
tion, was expected to be suitable and practical in clinical use. A
few multisession studies were reported. Five consecutive days of
rTMS resulted in remarkable pain relief in NP patients, lasting over
2 weeks in a parallel study [17], although the Cochrane review sug-
gested that this study had a high risk of bias in the randomization
process [31]. Meanwhile, another blinded, randomized crossover
study applying multisession rTMS to patients with spinal cord in-
jury (SCI) did not demonstrate positive effects in the short or long
term [16]. Of all the previous reports, adequate randomization and
blinding of assessors were done in only 4 studies (3 single sessions
evaluating a short-term effect [3,4,23] and one multisession [16]).
To establish the further clinical use of HF-rTMS of M1 for NP, a
well-designed, blinded, randomized controlled trial (RCT) of multi-
session rTMS is needed. In the current study, we aimed to assess
the safety and efﬁcacy of a daily 10-session of HF-rTMS targeting
M1 in patients suffering from NP, assessing not only the short-term
effects on pain, but also any cumulative effects.
2. Methods
2.1. Patients
This was a multicenter, randomized, double-blind, sham-con-
trolled, crossover study conducted at 7 centers in Japan from
August 2009 to December 2011. We enrolled patients aged
20 years or over who met the criteria for NP [29] and whose pain
lasted 6 months or longer despite adequate treatments. Exclusion
criteria were the inability to write the questionnaires, dementia,
aphasia, major psychiatric disease, suicidal wish, pregnancy, and
contraindications to TMS, like implantation of a cardiac pacemaker
[39]. Enrollment of participants, interventions, and assessments
were done in the study centers on an outpatient or inpatient basis.
As we studied an add-on effect of rTMS, the patients were asked
not to change their usual medications.
This RCT was conducted in accordance with Good Clinical Prac-
tice, the Declaration of Helsinki, and the Japanese ethical guide-
lines for clinical studies. The study protocol was thoroughly
reviewed and approved by institutional review boards and the eth-
ics committees of all the study institutions. All patients provided
written informed consent and assent before enrollment.
2.2. Randomization and masking
Before the patient enrollment, the independent data center
developed a randomization program to assign each patient to
one of 2 treatment groups (1:1). A real rTMS period was followed
by a sham period in group A, and a real rTMS period came after a
sham period in group B. We used Pocock and Simon’s minimization
method to stratify treatment groups according to institution, age
(<60 or P60 years), sex, and underlying disease (a cerebral lesion
or not), and the Mersenne twister for random number generation
[34].
After conﬁrmation of patient eligibility, the data center received
a registration form from an assessor who collected questionnaires
and assessed adverse events, and then sent an assignment notice to
an investigator who conducted the rTMS intervention. Patients
were identiﬁed by sequential numbers that were assigned by the
data center. Patients and assessors were blind to group assignment
until the study was completed. The data center was responsible for
assigning patients to a treatment group, data management, central
monitoring, and statistical analyses.2.3. Procedures
A session of the stimulation was applied daily for 10 consecu-
tive days, except for weekends, followed by a follow-up of at least
17 days. Typically, a stimulation period started on Monday (day 1)
and ended on Friday (day 12), and the follow-up lasted up to
Monday after 4 weeks (day 29). The same stimulation (real or
sham) was applied daily over the stimulation period. Real and
sham stimulation periods were separated by 17 days or longer.
This interperiod interval was based on the fact that signiﬁcant pain
relief was no longer observed 2 weeks after a single 5-Hz rTMS ses-
sion of 1500 pulses in 30 NP patients [15].
Fig. 1 shows the time schedule of the evaluations. Current pain
intensity was examined every day in each patient using a visual
analogue scale (VAS; scaled 0–100) and short-form McGill pain
questionnaire (SF-MPQ; scaled 0–45) [30] from the day before
intervention (day 0) to day 29. In the days with the intervention,
these scores were obtained before the intervention, just after,
and 60 min after the intervention. On the other days, patients were
asked to record the scores once a day at approximately the same
hour as the intervention. The Patient Global Impression of Change
(PGIC) [9] uses a 7-point scale from ‘‘very much improved’’ to ‘‘very
much worse.’’ A PGIC score was obtained on days 5, 12, 15, 22, and
29. In addition, the severity of depressive symptoms was measured
by the Beck Depression Inventory (BDI) on days 0, 1 (before the
intervention), 5 (after the intervention), 12 (after the intervention),
22, and 29. All items were recorded in uniﬁed forms by patients.
Blinded assessors rated these scales and recorded on case report
forms with or without observed adverse events.
The rTMS was applied through a ﬁgure-8 coil connected to a
magnetic stimulator, which provides a biphasic pulse (Magstim
Rapid, Magstim Company, UK; or AAA- 81077, Nihon Kohden Corp,
Tokyo, Japan). To keep the same conditions as sham stimulation,
sham electrodes were ﬁxed on the head during real stimulation.
The center of the coil was placed on M1 corresponding to a painful
region (face, hand, or foot). The optimal stimulus site, motor hot
spot, was ﬁnally determined according to visual detection of
muscle twitches, and a resting motor threshold was deﬁned as
the minimal intensity necessary to induce at least one visible mus-
cle twitch [13]. A real rTMS session consisted of 10 trains at 90%
intensity of resting motor threshold (one train, 50 pulses at 5 Hz;
intertrain interval, 50 s). A total of 500 pulses were applied in a ses-
sion. The detailed methods have been described in previous reports
[14,36]. This protocol was developed in accordance with the guide-
lines for the safe use of rTMS [39].
Realistic sham stimulation [32] was implemented in this study.
Ten trains of electrical stimuli at 2 times the intensity of the sen-
sory threshold (one train, 50 stimuli at 5 Hz; intertrain interval,
50 s) were delivered with a conventional electrical stimulator
through the electrodes ﬁxed on the head. The cortical effect of
the cutaneous electrical stimulation was considered to be negligi-
ble at this intensity because of the high electrical resistance of the
skull and brief duration of the stimulation [32]. A ﬁgure-8 coil,
which did not connect to a magnetic stimulator, was placed on
the head in the same manner as a real rTMS session. Another coil,
which discharged simultaneously with the electrical stimuli, was
placed near the unconnected coil to produce the same sound as
real rTMS, but not to stimulate the brain.
2.4. Statistical analysis
The primary outcome was a short-term change in the VAS, and
the secondary outcomes were short-term change in SF-MPQ,
cumulative changes in all the scores (VAS, SF-MPQ, PGIC, and
BDI), and the incidence of adverse events.
Fig. 1. Time schedule of evaluations. Current pain intensity was examined every day by visual analogue scale (VAS) and the short-form McGill pain questionnaire (SF-MPQ).
In the days with the intervention, these scores were obtained at 3 time points: before the intervention, just after, and 60 min after the intervention. Patient Global Impression
of Change (PGIC) was obtained on day 5, 12, 15, 22, and 29. The severity of depressive symptoms was measured by Beck Depression Inventory (BDI) on day 0, 1 (before the
intervention), 5 (after the intervention), 12 (after the intervention), 22, and 29.
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ducted 3 times in 30 NP patients. The mean VAS reduction rate
(SD) at 60 min after real rTMS was about 10% (10%) [15]. In this
study, assuming the expected VAS reduction rate of 5% (10%) and
a drop-out rate of 10%, we calculated that a sample size of 70 pa-
tients with a power of 80% for the Dunnett-Gent test at an a level
of 0.05 to detect the effect of rTMS. The projected study period was
2½ years, and no interim analysis was planned.
To evaluate carry-over effects, Grizzle’s test for carry-over effect
was applied to the values at day 0 for each period [12]. For the
short-term outcomes in VAS and SF-MPQ, reduction rates from
the values before the intervention in each day were used for statis-
tical analyses. The reduction rates after real rTMS and sham were
compared using a repeated-measures analysis of variance (ANOVA)
(intervention [real/sham], time [just after stimulation/60 min], day
[days 1–5, 8–12]; between-subject factor, period [ﬁrst/second]).
The positive effect was deﬁned as a mean short-term VAS reduc-
tion rate of P10% after subtracting the sham effect (real minus
sham), based on the reported criteria for a minimally clinically
important difference [9]. For the cumulative effects on VAS and
SF-MPQ during the intervention period, reduction rates at days
2–13 (values before the intervention were used at days 2–5 and
8–12) were used for statistical analysis. The reduction rates were
calculated from the average values of day 0 and 1. The daily
changes of each score were analyzed using a repeated-measures
ANOVA (within-subject factor, day [days 2–13]) in each group,
and intervention (a total of 4 data sets in each score: group A [real],
group A [sham], group B [real], group B [sham]). The direct effects
were calculated by Koch’s crossover nonparametric test [19] fol-
lowing Sidak’s multiple-comparison adjustment to evaluate PGIC
and BDI changes, because we compared between real rTMS and
sham for each time point (day 5, 12, 15, 22, and 29 for PGIC; day
5, 12, 22, and 29 for BDI). The efﬁcacy rates (a short-term VAS
reduction rate of P10%) were compared between subgroups (sex,
age, underlying disease, lesion site, treated painful region, pain lat-
erality, and previous treatment) with a Fisher’s exact test. To eval-
uate the inﬂuence of timing of the sham stimulation on a placebo
effect [2], the short-term reduction rates of VAS and SF-MPQ after
sham stimulation were compared between the following groups
with a one-way ANOVA (group A with a positive effect, group A
without a positive effect, and group B). In all analyses, ﬁndings
with P < 0.05 were considered statistically signiﬁcant.
The protocol was ﬁxed on May 2009 and this clinical trial was
registered with University hospital Medical Information Network
(UMIN) Clinical Trials Registry (UMIN-CTR) (http://www.umin.
ac.jp/ctr/index.htm), number UMIN000003048.3. Results
Fig. 2 shows the trial proﬁle. Seventy patients were enrolled and
randomly assigned to 2 groups. Of these patients, one patient never
came to the hospital after the registration, and a suicidal wish be-
came apparent before the start of the intervention in another
patient. Sixty-eight patients received the interventions and 64 pa-tients were included in the intention-to-treat analysis after exclud-
ing 4 patients without any data collection. Two patients in group A
discontinued the study during the real rTMS period for noncompli-
ance (n = 1) and urinary tract infection (n = 1). One patient in group
B discontinued participation during the sham period for personal
reasons. No patients discontinued due to adverse events associated
with the intervention. Table 1 shows baseline demographic and
clinical characteristics of the 64 patients assessed for efﬁcacy.
The participants were predominantly men, and the underlying dis-
eases were predominantly central poststroke pain (CPSP). Grizzle’s
test showed no carry-over effects in VAS and SF-MPQ (P = 0.361
and P = 0.286, respectively) [12].
3.1. Short-term effects of rTMS on VAS (primary outcome)
In the short term, the real rTMS showed more reductions of VAS
than the sham. The repeated-measures ANOVA revealed a signiﬁ-
cant effect of intervention (P < 0.001) and time (P < 0.001), but no
signiﬁcant effect of day (P = 0.325) or period (P = 0.464) (Fig. 3).
The mean VAS reduction rates (95% conﬁdence interval) of 10 aver-
aged sessions in real rTMS and sham were 6.51% (3.68–9.34) vs
2.44% (0.98–5.62) just after stimulation, and 3.38% (1.13–5.62) vs
0.66% (2.74–1.43) 60 min after stimulation. The deﬁned posi-
tive effect was observed in 12 of 61 patients (19.7%) who under-
went both real and sham stimulation. The mean values at each
time point are shown in Supplementary Table 1.
3.2. Short-term effects of rTMS on SF-MPQ
The short-term effect in SF-MPQ was similar to that of VAS. The
real rTMS showed more reductions of SF-MPQ than the sham. The
repeated-measures ANOVA revealed a signiﬁcant effect of inter-
vention (P = 0.002), time (P < 0.001), and day (P = 0.001), but no
signiﬁcant effect of period (P = 0.506) (Fig. 4). The mean SF-MPQ
reduction rates (95% conﬁdence interval) of 10 averaged sessions
in real rTMS and sham were 13.31% (8.24–18.39) vs 7.49% (3.45–
11.53) just after stimulation, and 5.11% (0.05–10.18) vs 3.62%
(9.27–2.03) 60 min after stimulation. The mean values at each
time point are shown in Supplementary Table 2.
3.3. Cumulative effects of rTMS on pain intensity, global impression of
change, and depression
In the analysis of cumulative effects in VAS and SF-MPQ, no sig-
niﬁcant daily changes were seen in the reduction rates for any con-
ditions (PP 0.05). PGIC scores were signiﬁcantly better in real
rTMS compared with sham during the intervention period but
not at the follow-ups (Fig. 5). The BDI changes did not show signif-
icant differences between the real rTMS and sham at any time
points (Fig. 6).
3.4. Subset analysis on the short-term effects of rTMS on pain intensity
The subset analyses did not show signiﬁcant differences in the
short-term rTMS efﬁcacy between each subgroup, although the
Fig. 2. Trial proﬁle. A ﬂow chart shows the study organizational structure, with the numbers of patients initially enrolled (n = 70), with patient dropouts noted at different
time points during the study. The ﬁnal number of patients in each treatment group is indicated.
Table 1
Patients’ characteristics (intention-to-treat analysis set).
Group A (n = 29) Group B (n = 35) Total (n = 64)
Sex (female) 13 (45%) 11 (31%) 24 (38%)
Age (years) 61.2 (10.9) 60.1 (10.5) 60.7 (10.6)
Underlying disease
Cerebral lesion (CPSP) 22 (76%) 30 (86%) 52 (81%)
Thalamus 15 14 29
Lenticular nucleus 6 12 18
Subcortex 1 2 3
Brain stem 0 2 2
Noncerebral lesion 7 (24%) 5 (14%) 12 (19%)
Spinal lesion 4 3 7
Phantom limb 1 2 3
Root avulsion 1 0 1
Peripheral nerve injury 1 0 1
Treated painful region
Right 14 21 35
Left 15 14 29
Face 5 1 6
Upper limb 13 22 35
Lower limb 11 12 23
Pain duration (months) 56.4 (63.1) 59.5 (47.0) 58.2 (10.6)
Previous treatment
Medication alone 22 (76%) 24 (69%) 46 (72%)
Nerve block 6 (21%) 6 (17%) 12 (19%)
Spinal cord stimulation (trial) 1 (3%) 3 (9%) 4 (6%)
Others 2 (7%) 3 (9%) 5 (8%)
Current medications
Anticonvulsants 23 (79%) 26 (74%) 49 (77%)
Antidepressants 12 (41%) 16 (46%) 28 (44%)
Benzodiazepines 6 (21%) 9 (26%) 15 (23%)
NSAIDs 5 (17%) 2 (6%) 7 (11%)
Muscle relaxants 1 (3%) 2 (6%) 3 (5%)
Opiates 1 (3%) 0 (0%) 1 (2%)
Total number of medications 1.86 (1.16) 1.91 (1.40) 1.89 (1.29)
VAS (baseline) (0–100 mm) 78.8 (17.8) 73.3 (17.6) 75.6 (17.6)
SF-MPQ (baseline) (0–45) 19.7 (9.5) 20.0 (9.7) 19.9 (9.5)
BDI (baseline) (0–63) 14.8 (12.9) 14.4 (7.9) 14.6 (10.2)
CPSP, central post-stroke pain; NSAIDs, nonsteroidal antiinﬂammatory drugs; VAS, visual analogue scale; SF-MPQ, short-form McGill pain questionnaire; BDI, Beck
Depression Inventory.
Data are expressed as means (SD), numbers (%), or numbers.
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lar nucleus tended to have relatively better pain relief (Fig. 7). Theanalgesic effects of the sham stimulation were not signiﬁcantly
different among the 3 groups. However, the sham following
Fig. 3. Short-term results of visual analogue scale (VAS) reduction rate (primary outcome). The mean reduction rates of VAS just after intervention are shown. The VAS
reduction rate was signiﬁcantly higher after real stimulation compared with sham.
Fig. 4. Short-term results of the short-formMcGill pain questionnaire (SF-MPQ) reduction rate. The mean reduction rates of SF-MPQ just after intervention are shown. The SF-
MPQ reduction rate was signiﬁcantly higher after real stimulation compared with sham.
Fig. 5. Mean Patient Global Impression of Change (PGIC). The PGIC scores were
signiﬁcantly better in real stimulation compared with sham at day 5 and 12, but not
at day 15, 22 or 29. PGIC: 1, very much improved; 2, much improved; 3, minimally
improved; 4, no change; 5, minimally worse; 6, much worse; 7, very much worse.
Fig. 6. Mean Beck Depression Inventory (BDI) reduction. The BDI reduction was not
different between real and sham stimulation.
K. Hosomi et al. / PAIN

154 (2013) 1065–1072 1069
Table 2
Adverse events.
Sham
(n = 66)
Real rTMS
(n = 67)
Total number of reported adverse
events
8 4
Deterioration of squeezing 2 (3%) 2 (3%)
Headache 2 (3%) 0
Deterioration of numbness 1 (2%) 1 (1%)
Hypoglycemia 0 1 (1%)
Anxiety 1 (2%) 0
Appetite loss 1 (2%) 0
Dizziness 1 (2%) 0
rTMS, repetitive transcranial magnetic stimulation.
Data are expressed as numbers (%) or numbers.
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SF-MPQ than that following unsuccessful real rTMS (Supplemen-
tary Table 3).
3.5. Adverse events
No serious adverse events related to the interventions were
observed. Table 2 shows adverse events observed during the study.
The incidence of headache, deterioration of squeezing, or
deterioration of numbness was not higher during the real rTMS
period compared with the sham.
4. Discussion
This double-blinded RCT of multisession rTMS showed the
short-term positive effect on NP without any serious adverse
events. However, it showed no cumulative effect during daily
stimulation.
This is the ﬁrst multisession double-blinded RCT to demon-
strate the positive short-term effects. Around 20 randomized or
quasi-randomized studies testing the feasibility of rTMS as a treat-
ment for pain relief in patients with chronic pain were reported be-
fore the end of 2011 [3,4,7,14,16,17,21–25,27,31,33,35,36]. Our
previous study showed that relief of NP was observed only when
targeting M1, but not in the other areas [14]. Regarding the
short-term effect from a single session of rTMS, most studies and
meta-analyses, including the Cochrane review [31], demonstrated
positive effects on pain relief after HF-rTMS of M1, but not after
low frequency. However, the Cochrane review found only 3 studies
[3,4,23] after restriction to RCTs in which there was adequate
blinding of assessors. One study showed a negative result [4], while
the meta-analysis of these 3 studies showed favorable results for
real rTMS [31]. Multi-session HF-rTMS of M1 was applied in aFig. 7. Forest plot of subgroup analyses. The short-term efﬁcacy rate (visual
analogue scale reduction rate subtracting sham of P10%) of each subgroup is
shown. The 95% conﬁdence intervals (CIs) were calculated by the exact binomial
conﬁdence interval method for proportions.few studies (2 for SCI, [7,16] one for CPSP and trigeminal neuralgia
[17], and one for ﬁbromyalgia [33]). The daily rTMS on NP led to
remarkable long-lasting pain relief in a parallel study [17],
although the Cochrane review suggested that the study had a high
risk of bias in the randomization process [31]. And then 2 multises-
sion studies for SCI failed to show a positive effect of rTMS [7,16].
Thus, only a few well-designed double-blinded RCTs applying sin-
gle-session rTMS were reported, and the short-term effect on NP
had not been established for multisession rTMS. This multisession
study, in which the number of participants was the largest and par-
ticipants were restricted to NP patients, has conﬁrmed the short-
term effect on NP recognized in previous single-session studies.
With regard to long-term effects, or cumulative effects, there were
not enough previous studies to reach solid conclusions. The pres-
ent study also did not show cumulative effects on pain or depres-
sion, although PGIC tended to be better in real rTMS during the
intervention period. On account of the transient effects and the
lack of cumulative effects, our ﬁndings suggest that repeated daily
rTMS would be necessary for continuous pain relief. If a handheld
portable device [28] is developed for rTMS, it will be possible to
administer rTMS more than once a day with similar uses as EMCS,
which is normally used several times a day [37], although this por-
table procedure needs a further clinical trial to prove its treatment
accuracy and efﬁcacy.
The previous meta-analyses of HF-rTMS of M1 for NP calculated
effect sizes corresponding to a pain reduction of 12% and 13.7% on
a VAS [27,31]. The reduction rate subtracting the sham and the efﬁ-
cacy rate were relatively small in this study compared with those
reported in previous reports. It may be partially due to the pre-
dominance of CPSP (81%) and elderly participants in this study.
The mean age was higher in the current study compared with pre-
vious studies (60.7 years vs 52–57 years) [3,14,21–25]. Our previ-
ous study reported a lesser effect in CPSP and elderly patients,
and others reported larger effects in trigeminal and peripheral
NP [15,24,27,36]. It is well known that CPSP is extremely difﬁcult
to treat with available therapies [18]. Another possible reason for
the modest pain relief reported here may be the suboptimal proce-
dure used in the present study. The frequency of 5 Hz was rela-
tively low compared to that of 10 or 20 Hz applied in most
previous studies [3,4,16,17,21–25,33,35]. The number of pulses
per session in this study was lower than in most previous studies
(500 pulses vs 1000–2000 pulses) [3,4,16,17,21–25,33], and the to-
tal number of pulses per treatment was also relatively small com-
pared with other studies (5000 pulses vs 10,000–20,000 pulses)
[17,33]. Furthermore rTMS was discontinued on weekends in the
present study. Thus, the stimulation conditions used in the present
study were modest relative to previous studies. Lefaucheur et al.
reported better results using stimulation of the motor cortex
region adjacent to that corresponding to the painful site [26].
Therefore, the stimulation to the region corresponding to the
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More optimal conditions of stimulation may enhance the efﬁcacy
of rTMS in pain relief, for example higher frequency of stimulation,
a larger number of stimuli, and stimulation to a more optimal
region.
It has been suggested that the underlying pathophysiology of
NP is associated with plastic changes and dysfunction of extensive
neural circuits in the central nervous system, involving various
structures related to pain perception, and with an affective-emo-
tional component [27]. The possible mechanisms of action of pain
relief following the stimulation of M1, either EMCS or rTMS, are
considered to be modulation of neural activity in these structures
[20]. The process of pain relief obtained by rTMS or EMCS is as-
sumed that the stimuli act locally within M1, representing an entry
port point, and modulates the above remote, deep brain structures
through the subcortical ﬁbers [10,11,22]. These hypotheses of cere-
bral modulation in the various central nervous system structures
could explain the effects of rTMS lasting more than 60 min.
A recent study discussing a placebo effect in rTMS for NP dem-
onstrated that timing of sham stimulation (before vs after real
rTMS) and the efﬁcacy of preceding real rTMS inﬂuenced the efﬁ-
cacy of the sham stimulation [2]. Although our results did not
reach signiﬁcant differences, the successful real rTMS prior to the
sham tended to enhance the placebo effect, and the unsuccessful
one tended to reduce it. These ﬁndings might reproduce the results
of the previous report. As the previous report mentioned, the pla-
cebo timing and the effect of preceding real rTMS should be taken
into account in rTMS studies for pain.
Our study has several potential limitations. First, the possibility
of unblinding should be considered. To conceal the types of inter-
vention from the patients, we adopted realistic sham stimulation
with simultaneous electrical stimulation on the scalp and kept
the conditions as similar as possible between real and sham. The
assessors were also blinded to the treatment, although all scales
were self-reported by patients. However, as a participant receives
both real and sham stimulation in a crossover study, the possibility
of unblinding cannot be eliminated completely. A parallel design
should be considered for future studies. Second, the underlying
disease of our subjects was heterogeneous and was dominated
by CPSP (81%). Our results should be applied to the general popu-
lation of NP patients with caution. Third, quality of life, activities of
daily living, and consumption of drugs were not measured in this
study. Multifaceted evaluations including these measurements
should be considered in future studies.
The noninvasive property of rTMS is one of its major clinical
advantages. The use of rTMS for treatment of NP patients was
not accompanied by any serious adverse events in this study or
in previous studies. The multisession rTMS has been conﬁrmed
to be generally safe in selected patients with NP.
Our ﬁndings demonstrate that daily HF-rTMS of M1 is tolerable
and transiently effective for pain relief in patients with NP. How-
ever, this effect is still modest and varies between individuals.
rTMS may not demonstrate genuine clinical utility under the con-
dition of our study including nonresponders. In the future, treat-
ment with repeated daily rTMS should be administered to
selected patients with successful pain relief in prior rTMS trials,
similar to procedures followed for other neurostimulation thera-
pies like EMCS [37] and spinal cord stimulation [1].Conﬂict of interest statement
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